Vascular ECs themselves produce abundant molecules, which play a crucial role in EC protection. 8 EC-dependent relaxation is mediated by prostacyclin, NO, and endothelium-derived hyperpolarizing factors. 9 Prostacyclin and NO stimulate the production of cAMP and cGMP, respectively, in adjacent VSMCs. 8 cAMP and cGMP promote VSMC relaxation and inhibit VSMC proliferation, migration, and extracellular matrix production. Cyclic nucleotide phosphodiesterases regulate the intracellular cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and cGMP to 5′AMP and 5′GMP. 7 Among the various phosphodiesterase isozymes expressed in different types of VSMCs, 1C (PDE1C), which hydrolyzes both cAMP and cGMP, is induced in synthetic VSMCs 10 and promotes VSMC proliferation. 11 In this issue of Circulation Research, Cai et al 12 designed experiments to understand the regulation and function of phosphodiesterases in the modulation of VSMC phenotype, and the mechanism whereby PDE1C promotes VSMC proliferation. The authors demonstrate that PDE1C is an important regulator not only of VSMC proliferation but also of VSMC migration and neointimal hyperplasia, and that the mechanism involves, at least in part, endosome/lysosome-dependent platelet-derived growth factor receptor β (PDGFRβ) degradation and degradation of other growth factor receptors ( Figure) . First, to understand the specific cyclic nucleotide signaling pathway responsible for the synthetic VSMC phenotype, the authors performed screening for phosphodiesterase isozymes that are specifically expressed in synthetic VSMCs when compared with those in contractile VSMCs. The authors found that the PDE1C isozyme is significantly upregulated in synthetic VSMCs, consistent with previous studies. 10 Next, the authors used in vitro and in vivo approaches and demonstrated that PDE1C plays a causative role in synthetic VSMC proliferation/migration and intimal hyperplasia. 12 Finally, the authors elucidated the molecular mechanism by which PDE1C promotes the protein stability of PDGFRβ and other growth factor receptors via negatively regulating endosome/lysosome-mediated degradation in an low-density lipoprotein receptor-related protein 1 (LRP1)-dependent manner ( Figure) .
PDGF receptor signaling has a variety of actions in VSMCs, including proliferation, migration, protein production/secretion, and phenotypic modulation. Therefore, this study provides novel information about the role of PDE1C in PDGF signaling, which serves as an important multifunctional regulator in synthetic VSMCs. Elevation of cAMP generated by transmembrane adenylyl cyclase activates cAMP-dependent protein kinase A, then phosphorylates LRP1, and promotes endocytosis of PDGFRβ, which proceeds to lysosome-mediated
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PDGFRβ degradation and subsequently reduces the PDGFRβ protein level (Figure) . Consistently, previous studies have shown that LRP1 depletion in VSMCs resulted in elevated PDGFRβ level and activation, increased VSMC proliferation and migration, and accelerated atherosclerosis and aortic aneurysm in VSMC-specific LRP1 knockout mice. 13 LRP1 plays diverse roles in a variety of biological processes, including lipoprotein metabolism, clearance of plasma proteins, protease degradation, as well as receptor trafficking and signaling. This study clearly demonstrates that LRP1 is important in PDE1C/ cAMP-mediated regulation of PDGFRβ stability and availability. Based on this study and the previous reports, cAMP/ PKA directly modulates LRP1 function, likely through PKA phosphorylation of LRP1. cAMP might also regulate VSMC phenotypic change by modulating RhoA activity and downstream Rho-kinase (Figure) . Taken together, these data implicate the induction of PDE1C as an important component of VSMC phenotypic change from the contractile to synthetic state.
Clinical Perspectives
The authors have shown that PDE1C regulates soluble adenylyl cyclase/cAMP signaling and lysosome-mediated collagen I protein degradation.
14 Besides in VSMCs, PDE1C is also expressed in human cardiac myocytes with an intracellular distribution distinct from that of phosphodiesterase 3A. 15 These findings may have great therapeutic impact as it may lead to the development of novel therapeutic strategies using PDE1C-selective inhibitors for cardiovascular diseases. 16 Here, blockade of PDGFR signaling by oral administration of Imatinib (a tyrosine kinase inhibitor) has been shown to inhibit pulmonary VSMC proliferation and ameliorate the development of pulmonary arterial hypertension (PAH). 17, 18 The pathobiology of PAH includes EC dysfunction, VSMC proliferation/migration, and inflammation. [19] [20] [21] [22] [23] PDGF has been implicated in these processes 24 and altered PDGF signaling is involved in the vascular remodeling observed in PAH. 22 Thus, PDE1C may represent a novel therapeutic target for VSMC phenotypic modulation in systemic hypertension, aneurysms, and PAH. 25 The present findings in VSMCs may also be applicable to pulmonary artery PDE1C) is an important regulator of vascular smooth muscle cell (VSMC) phenotypic change in part through modulating endosome/lysosome-dependent growth factor receptor internalization and endocytosis. Cyclic nucleotide PDE1C upregulation antagonizes the transmembrane adenylyl cyclase (tmAC)-cAMP-cAMP-dependent protein kinase A (PKA) signaling and thus suppresses growth factor receptor (GFR) degradation, which facilitates VSMC phenotype modulation. Low-density lipoprotein receptor-related protein 1 (LRP1) is an important mediator in PDE1C-cAMP regulation of GFR protein degradation. Internalized GFRs have many different fates: sustained signaling within early endosomes, recycling to the plasma membrane, or trafficking to lysosomes for degradation. GFR endocytosis and lysosome degradation prevent sustained growth factor activation on the plasma membrane. Ras homolog gene family member A (RhoA) acts as a molecular switch that cycles between an inactive GDP-bound and an active GTP-bound conformation interacting with downstream targets to elicit a variety of cellular responses. The activity of RhoA is controlled by the guanine nucleotide exchange factors (GEFs) that catalyze exchange of GDP for GTP. In contrast, GTPase activating proteins (GAPs) stimulate the intrinsic GTPase activity and inactivate RhoA. Here, cAMP-exchange protein activated by cAMP (Epac)-Rap1 activation regulates GAPs, which contribute to RhoA inactivation and potentially contribute to the VSMC phenotypic switch. 
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VSMCs, and PDE1C inhibition may represent a novel strategy to target PDGFR degradation in PAH. Because PDE1C is markedly induced in synthetic VSMCs, PDE1C inhibitors may show less adverse effects compared with Imatinib. Highly selective PDE1C inhibitors that can target synthetic VSMCs are likely to be developed in the near future. Additionally, clinical trials will be required to investigate whether inhibition of PDE1C prevents the development of PAH, in which the phenotypic change of VSMCs from a quiescent state to a proliferating state significantly contributes to the underlying pathology.
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